SI9520118A - Sestavki in zdravljenje multiple skleroze - Google Patents

Sestavki in zdravljenje multiple skleroze Download PDF

Info

Publication number
SI9520118A
SI9520118A SI9520118A SI9520118A SI9520118A SI 9520118 A SI9520118 A SI 9520118A SI 9520118 A SI9520118 A SI 9520118A SI 9520118 A SI9520118 A SI 9520118A SI 9520118 A SI9520118 A SI 9520118A
Authority
SI
Slovenia
Prior art keywords
seq
mbp
peptide
peptides
group
Prior art date
Application number
SI9520118A
Other languages
English (en)
Slovenian (sl)
Inventor
Dawn Smilek
Michael Samson
Malcolm Gefter
Di-Hwei Hsu
Jia-Dong Shi
Xavier Paliard
Brigitte Devaux
Jonathan Rothbard
Henry Franzen
Original Assignee
Immulogic Pharmaceutical Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immulogic Pharmaceutical Corporation filed Critical Immulogic Pharmaceutical Corporation
Publication of SI9520118A publication Critical patent/SI9520118A/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/215IFN-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rehabilitation Therapy (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SI9520118A 1994-10-25 1995-10-25 Sestavki in zdravljenje multiple skleroze SI9520118A (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32822494A 1994-10-25 1994-10-25
US40422895A 1995-03-15 1995-03-15
PCT/US1995/013682 WO1996012737A2 (fr) 1994-10-25 1995-10-25 Compositions et traitement pour la sclerose en plaques

Publications (1)

Publication Number Publication Date
SI9520118A true SI9520118A (sl) 1998-08-31

Family

ID=26986277

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9520118A SI9520118A (sl) 1994-10-25 1995-10-25 Sestavki in zdravljenje multiple skleroze

Country Status (15)

Country Link
EP (1) EP0787147A1 (fr)
JP (1) JPH10504039A (fr)
AU (1) AU4278296A (fr)
BR (1) BR9509438A (fr)
CA (1) CA2203629A1 (fr)
CZ (1) CZ122697A3 (fr)
FI (1) FI971750A (fr)
HU (1) HUT77047A (fr)
IL (1) IL115766A0 (fr)
IS (1) IS4466A (fr)
NO (1) NO971900L (fr)
PL (1) PL324091A1 (fr)
SI (1) SI9520118A (fr)
SK (1) SK51297A3 (fr)
WO (1) WO1996012737A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6252040B1 (en) * 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US6156535A (en) 1995-08-04 2000-12-05 University Of Ottawa Mammalian IAP gene family, primers, probes, and detection methods
CA2247009C (fr) 1996-03-21 2009-08-04 Imperial College Of Science, Technology And Medicine Peptides cryptiques et leur procede d'identification
EP0939826A2 (fr) * 1996-08-15 1999-09-08 Agrivax Incorporated Administration d'antigenes tolerogeniques via des plantes comestibles ou des produits derives de plantes
CA2494338C (fr) * 1997-04-04 2007-07-17 The Governors Of The University Of Alberta Specificite des peptides de la proteine basique anti-myeline et administration de ces peptides aux patients atteints de sclerose en plaques
SE9703287D0 (sv) * 1997-09-11 1997-09-11 Astra Ab Peptides
CN1308671A (zh) * 1998-05-05 2001-08-15 科里克萨公司 髓磷脂碱性蛋白肽及其应用
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
WO1999060021A2 (fr) * 1998-05-19 1999-11-25 Yeda Research And Development Co. Ltd. Lymphocytes t actives, antigenes specifiques du systeme nerveux et leur utilisation
EP1288226A1 (fr) * 2001-09-03 2003-03-05 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Modification de l'expression des gènes pour les récepteurs type "Toll" destinée à influencer la neurodégénérescence et la neuroprotection de système nerveux central de l'homme
GB0202399D0 (en) * 2002-02-01 2002-03-20 Univ Bristol Peptide
DE60327618D1 (de) 2002-03-27 2009-06-25 Aegera Therapeutics Inc Gegen iap gerichtete antisense-nukleobasen und deren verwendungen
DE10230381A1 (de) 2002-07-05 2004-01-22 Institut für Medizintechnologie Magdeburg GmbH, IMTM Verwendung von Inhibitoren der Alanyl-Aminopeptidasen und diese umfassende pharmazeutischen Zubereitungen
US8012944B2 (en) 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
WO2008130382A2 (fr) 2006-10-31 2008-10-30 East Carolina University Protéines de fusion à base de cytokine pour le traitement de troubles immunitaires
US8815794B2 (en) * 2008-08-28 2014-08-26 The Research Foundation For The State University Of New York Treatment of amyloidoses using myelin basic protein and fragments thereof
EP3348275A3 (fr) * 2009-03-31 2018-10-24 East Carolina University Cytokines et neuroantigènes utilisés dans le traitement de troubles immunitaires
EA024832B1 (ru) 2009-10-12 2016-10-31 ЛАЙФБИО ЛАБОРАТОРИС ЭлЭлСи Олигопептид, связывающий гидролизующие аутоантитела к основному белку миелина mbp, композиции и способ лечения рассеянного склероза
RU2448685C2 (ru) * 2009-11-30 2012-04-27 Российская Федерация в лице Министерства промышленности и торговли Российской Федерации Липосомы, содержащие олигопептиды - фрагменты основного белка миелина, фармацевтическая композиция и способ лечения рассеянного склероза
CA2830772C (fr) 2011-03-21 2020-04-28 Atlantic Cancer Research Institute Polypeptides presentant une affinite pour les proteines de choc thermique (hsp) et complexes associes a une hsp (hacs) et leur utilisation en diagnostic et en therapie
EP3094341B1 (fr) 2014-01-13 2019-10-02 Berg LLC Compositions d'énolase 1 (eno1) et leurs utilisations

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2512796B2 (ja) * 1987-06-24 1996-07-03 オートイミュン・インコーポレイテッド 自己抗原の経口投与による自己免疫疾患の治療法
US5260422A (en) * 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
DK0506785T3 (da) * 1989-12-20 2000-07-24 Autoimmune Inc Forbedret behandling af autoimmune sygdomme ved aerosol-administration af autoantigener
EP0782859A1 (fr) * 1990-03-02 1997-07-09 Autoimmune, Inc. Amélioration de la régulation reductrice de maladies autoimmunes par administration orale d'autoantigènes
IL165071A (en) * 1990-03-30 2008-06-05 Autoimmune Inc A peptide with the ability to stimulate a subset of T cells from multiple sclerosis patients
CA2053799C (fr) * 1991-10-22 2002-03-12 Kenneth G. Warren Specificite pour les peptides synthetiques de la proteine basique anti-myeline presente dans le liquide cephalorachidien de patients atteints de la sclerose en plaques
EP0661996A4 (fr) * 1991-11-19 1997-05-21 Anergen Inc Conjugues d'une subunite du complexe majeur d'histocompatibilite utiles pour ameliorer les reponses immunitaires deleteres.
BR9306042A (pt) * 1992-02-28 1997-11-18 Autoimmune Inc Método para tratar uma doença auto-immune em um mamifero e formas de dosagens farmacêuticas oral e inalável
IL105153A (en) * 1992-03-25 1999-12-22 Immulogic Pharma Corp Therapeutic compositions comprising peptides derived from human t cell reactive feline protein
DE69320967T2 (de) * 1992-04-09 1999-05-12 Autoimmune Inc Unterdrückung der t-zell proliferation mittels peptidfragmenten des myelin basischen protein
WO1993025661A1 (fr) * 1992-06-10 1993-12-23 President And Fellows Of Harvard College Clones heterogenes de cellules t specifiques contre le peptide proteolipidique 139-151
WO1994004121A1 (fr) * 1992-08-17 1994-03-03 Autoimmune, Inc. Suppression par un antigene tiers d'une maladie neurologique associee a un retrovirus
NZ273813A (en) * 1993-09-03 1998-05-27 Immulogic Pharma Corp Myelin oligodendrocyte glycoprotein autoantigen
WO1995007096A1 (fr) * 1993-09-06 1995-03-16 La Trobe University Traitement de maladies auto-immunes
CA2172512A1 (fr) * 1993-09-22 1995-03-30 Lawrence Steinman Interaction de recepteurs de cellules t et d'antigenes dans des maladies auto-immunes
AU686797B2 (en) * 1994-04-08 1998-02-12 Brigham And Women's Hospital Treatment of autoimmune disease using oral tolerization and/or type I interferon
WO1995027500A1 (fr) * 1994-04-08 1995-10-19 Brigham And Women's Hospital TRAITEMENT DE MALADIES AUTO-IMMUNES AVEC DES AGENTS D'INDUCTION DE TOLERANCE ET/OU DES CYTOKINES DE RENFORCEMENT DES Th2 ADMINISTRES PAR VOIE ORALE
JPH10500109A (ja) * 1994-05-10 1998-01-06 イミユロジク・フアーマシユーチカル・コーポレーシヨン 多発性硬化症のための組成物および治療方法
JP3558347B2 (ja) * 1994-06-09 2004-08-25 ネーデルランセ オルハニサチエ フォール トゥーヘパスト−ナツールウェーテンシャッペルック オンデルズク テーエヌオー 自己免疫疾患、とくに多発性硬化症の診断および治療における使用のためのアルファbクリスタリン
US6329499B1 (en) * 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
CA2205532A1 (fr) * 1994-11-18 1996-05-30 Neurocrine Biosciences, Inc. Methodes de traitement de la sclerose en plaques par l'emploi d'analogues peptidiques a la position 91 de la proteine basique de la myeline humaine

Also Published As

Publication number Publication date
HUT77047A (hu) 1998-03-02
IS4466A (is) 1997-04-17
NO971900D0 (no) 1997-04-24
BR9509438A (pt) 1997-12-23
SK51297A3 (en) 1998-03-04
FI971750A0 (fi) 1997-04-24
NO971900L (no) 1997-06-25
CZ122697A3 (en) 1997-09-17
JPH10504039A (ja) 1998-04-14
WO1996012737A3 (fr) 1996-10-10
AU4278296A (en) 1996-05-15
WO1996012737A2 (fr) 1996-05-02
FI971750A (fi) 1997-06-24
IL115766A0 (en) 1996-01-19
PL324091A1 (en) 1998-05-11
EP0787147A1 (fr) 1997-08-06
CA2203629A1 (fr) 1996-05-02

Similar Documents

Publication Publication Date Title
US5858980A (en) Peptide fragments of myelin basic protein
SI9520118A (sl) Sestavki in zdravljenje multiple skleroze
US8343500B2 (en) Peptide composition
AU760864B2 (en) Novel peptides for the treatment, prophylaxis, diagnosis and monitoring of autoimmune diseases
WO1996012737A9 (fr) Compositions et traitement pour la sclerose en plaques
JP3434510B2 (ja) ミエリン塩基性タンパク質のペプチドフラグメントを用いたt‐細胞増殖の抑制
NO314878B1 (no) Fremgangsmåte for fremstilling av et farmasöytisk preparat for behandling av reumatoid artritt og multippel sklerose
JP2607751B2 (ja) 自己免疫性ブドウ膜網膜炎の治療予防薬
JPH09502346A (ja) 自己免疫疾患に関連するプロトコールにおけるミエリン希突起神経膠細胞糖蛋白質およびそのペプチド部分の使用
EP0922057A1 (fr) Peptides de la glycoproteine d'oligodendrocyte de myeline et leurs utilisations
KR20040108650A (ko) 미엘린 염기성 단백질 기원의 면역허용원 펩타이드
EP0788512B1 (fr) Composes de peptide de pro-insuline utiles pour detecter et traiter le diabete du type i
US6509165B1 (en) Detection methods for type I diabetes
AU738564B2 (en) Proinsulin peptide compounds for detecting and treating type I diabetes
EP3860644A1 (fr) Polypeptides recombinants comprenant des domaines dra1 de classe ii du cmh modifiés et procédés d'utilisation
AU9724801A (en) Proinsulin peptide compounds for detecting and treating type I diabetes